ResMed Inc (RMD)

Debt-to-capital ratio

		Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	5,967,860	5,546,130	5,253,010	5,195,030	4,864,040	4,629,920	4,481,850	4,250,380	4,129,900	3,932,510	3,738,130	3,432,890	3,360,750	3,278,800	3,145,840	3,026,050	2,885,680	2,709,230	2,864,980	2,678,860
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

June 30, 2025 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $5,967,860K)
= 0.00

The provided data indicates that ResMed Inc. has maintained a debt-to-capital ratio of zero across all reported periods from September 30, 2020, through June 30, 2025. This consistent zero value suggests that the company has not reported any long-term or short-term debt during this timeframe. As a result, the company’s capital structure appears to be entirely equity-financed, with no reliance on debt financing.

This debt-free status over multiple years and quarters may imply that ResMed Inc. operates with low financial leverage, potentially reducing its financial risk associated with debt obligations. It also indicates that the company likely funds its operations and growth through retained earnings, equity issuance, or other non-debt sources.

Overall, the absence of debt implicated by this consistent zero debt-to-capital ratio reflects a conservative financing approach, emphasizing equity capital and possibly emphasizing operational cash flows to support ongoing and future activities.